hoxb2a Antibody

What is HOXB2/hoxb2a and why is it significant in research?

HOXB2 is a homeobox transcription factor that plays crucial roles in developmental processes and has emerging significance in cancer biology. In vertebrates like zebrafish, hoxb2a is the orthologous gene with conserved functions. Recent studies have demonstrated HOXB2's tumor-suppressive role in triple-negative breast cancer (TNBC) through regulation of extracellular matrix (ECM) organization . HOXB2 functions by binding to the promoter regions of genes like MATN3 and ECM2 to regulate their transcription, thus affecting cancer progression and metastasis . The study of HOXB2/hoxb2a contributes to our understanding of both developmental biology and pathological processes.

How are HOXB2/hoxb2a antibodies typically generated for research purposes?

HOXB2/hoxb2a antibodies are commonly generated using synthetic peptide immunogens conjugated to carrier proteins like KLH (Keyhole Limpet Hemocyanin). Commercial antibodies often target specific amino acid sequences, such as AA 65-160 or the N-terminal or C-terminal regions of the protein . Polyclonal antibodies are typically produced by immunizing rabbits with these conjugated peptides, followed by purification using Protein A affinity chromatography . This approach yields antibodies suitable for multiple applications, including ELISA, immunohistochemistry on frozen sections (IHC-fro), and immunohistochemistry on paraffin-embedded sections (IHC-p) . For monoclonal antibody production, a similar initial immunization process would be followed by hybridoma generation, screening, and expansion of single B-cell clones producing the desired antibody.

What are the key considerations for selecting appropriate control samples for HOXB2/hoxb2a antibody validation?

Proper validation of HOXB2/hoxb2a antibodies requires carefully selected controls:

• Positive controls: Tissues or cell lines with confirmed HOXB2/hoxb2a expression, preferably validated by orthogonal methods such as qPCR or RNA-seq

• Negative controls:

  • Tissues or cell lines with undetectable HOXB2/hoxb2a expression

  • HOXB2/hoxb2a knockout samples (when available)

  • Secondary antibody-only controls to assess non-specific binding

• Peptide competition assays: Pre-incubation of the antibody with the immunizing peptide should abolish specific staining

• Cross-species validation: When using antibodies across different species (e.g., human HOXB2 antibodies for detecting zebrafish hoxb2a), sequence homology analysis and empirical validation are essential

Validation is particularly important given that HOXB2 expression patterns vary by cancer subtype, with specific downregulation observed in aggressive triple-negative breast cancers .

What are the optimal sample preparation methods for detecting HOXB2/hoxb2a in different experimental contexts?

Sample preparation requirements vary by application:

For Western Blotting:

• Cells/tissues should be lysed in RIPA or NP-40 buffer supplemented with protease inhibitors

• Nuclear extraction protocols are recommended as HOXB2/hoxb2a is a nuclear protein

• Sample denaturation at 95°C for 5 minutes in Laemmli buffer with reducing agent

For Immunohistochemistry (IHC):

• Formalin-fixed paraffin-embedded (FFPE) tissues: Antigen retrieval is critical, typically using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) with heat treatment

• Frozen sections: Brief fixation (4% paraformaldehyde, 10 minutes) followed by permeabilization with 0.1% Triton X-100

• Blocking with appropriate serum (5-10%) to reduce background

For Chromatin Immunoprecipitation (ChIP):

• Crosslinking with 1% formaldehyde for 10 minutes at room temperature

• Sonication to generate DNA fragments of 200-500 bp

• Immunoprecipitation buffer containing protease inhibitors and potentially phosphatase inhibitors

The HRP-conjugated HOXB2 antibody described in the search results has been validated for IHC applications on both frozen and paraffin-embedded sections , making it versatile for histological studies.

How can researchers accurately quantify HOXB2/hoxb2a protein levels in experimental samples?

Several quantitative approaches can be employed:

ELISA-based quantification:

• Direct ELISA: Coat plates with protein lysate and detect with anti-HOXB2 antibody

• Sandwich ELISA: Use capture and detection antibodies targeting different HOXB2/hoxb2a epitopes

• Standard curves generated with recombinant HOXB2/hoxb2a protein enable absolute quantification

Western blot densitometry:

• Normalize HOXB2/hoxb2a band intensity to loading controls (β-actin, GAPDH, or histone H3)

• Include concentration standards on each blot for relative quantification

• Use specialized software (ImageJ, Image Lab) for analysis

Mass spectrometry-based proteomics:

• Targeted approaches like selected/multiple reaction monitoring (SRM/MRM)

• SILAC or TMT labeling for accurate relative quantification

• Inclusion of isotope-labeled peptide standards for absolute quantification

The HRP-conjugated HOXB2 antibody mentioned in the search results has been validated for ELISA applications , making it suitable for quantitative studies when properly calibrated against standards.

What experimental strategies can determine HOXB2/hoxb2a binding to DNA and its transcriptional targets?

Several complementary approaches should be employed:

Chromatin Immunoprecipitation (ChIP):

• Standard ChIP followed by qPCR for known targets like MATN3 and ECM2

• ChIP-seq for genome-wide binding site identification

• CUT&RUN or CUT&Tag as alternatives with potentially higher signal-to-noise ratio

Functional validation of binding sites:

• Luciferase reporter assays with wild-type and mutated binding sites

• EMSA (Electrophoretic Mobility Shift Assay) to confirm direct binding

• CRISPR-based editing of putative binding sites

Integrative approaches:

• Combine ChIP-seq with RNA-seq after HOXB2/hoxb2a modulation to identify direct transcriptional targets

• Motif analysis to define consensus binding sequences

Research has confirmed that HOXB2 directly binds to the promoter regions of MATN3 and ECM2 genes to regulate their transcription, affecting ECM organization and cancer progression . Similar approaches can be used to identify additional targets in different biological contexts.

How does HOXB2/hoxb2a expression change during embryonic development, and what methods best capture these dynamics?

HOXB2/hoxb2a shows dynamic expression during development, particularly in the hindbrain where it contributes to rhombomere identity. Based on the search results and extended knowledge:

Temporal expression patterns:

• In zebrafish, hoxb2a expression is maintained by Hoxb1a after initial activation by Hoxb1b

• Expression is regulated through complex enhancer elements responding to upstream Hox factors

Methodological approaches for developmental studies:

• Whole-mount in situ hybridization: Optimal for spatial resolution in embryos

• Transgenic reporter lines: GFP/RFP under hoxb2a regulatory elements for live imaging

• Single-cell RNA-seq: For cell-type specific expression patterns

• ChIP-seq time course: To track epigenetic changes at the hoxb2a locus

• 4D imaging: For real-time tracking of expression in developing embryos

Epigenetic regulation during development:

• The hoxb2a promoter shows early histone modifications including H3K27ac and H4ac by 2 hours post-fertilization (hpf)

• H3K4me3 marks appear by 6 hpf, before detectable transcription

• H3K27me3 repressive marks are also present early but are reduced upon TALE factor binding

These findings indicate that hoxb2a undergoes complex epigenetic priming for later expression during development, with TALE factors playing a crucial role in this process.

What is the role of HOXB2 in cancer progression, and how can antibody-based approaches help elucidate these mechanisms?

HOXB2 has emerging roles in cancer biology with context-dependent functions:

Tumor-suppressive functions in TNBC:

• HOXB2 is specifically downregulated in aggressive triple-negative breast cancer

• It restrains TNBC aggressiveness by maintaining ECM organization through regulation of MATN3 and ECM2

• Forced expression of HOXB2 prevents TNBC progression and metastasis in mouse xenograft models

Antibody-based research approaches:

• Tissue microarray (TMA) analysis: Compare HOXB2 levels across cancer subtypes and correlate with clinical outcomes

• Proximity ligation assay (PLA): Detect HOXB2 interactions with transcriptional cofactors

• ChIP-seq in cancer models: Identify altered binding patterns in different cancer contexts

• Immunoprecipitation-mass spectrometry (IP-MS): Discover novel HOXB2 protein interaction partners in normal vs. cancer cells

Mechanistic insights:

• HOXB2 expression is regulated by a lncRNA (HOXB-AS1) in complex with SMYD3, a lysine methyltransferase

• This complex promotes H3K4me3 enrichment at the HOXB2 promoter, driving its expression

• Reduced HOXB2 correlates with increased expression of EMT markers like CDH2 and VIM

These findings highlight the potential of HOXB2 as a biomarker and therapeutic target, particularly in TNBC, with antibody-based detection being central to these investigations.

How can researchers differentiate between HOXB2 and other closely related HOX proteins in experimental settings?

Distinguishing between highly homologous HOX proteins requires careful experimental design:

Antibody selection strategies:

• Target non-homeodomain regions that show greater sequence divergence

• Use peptide arrays to screen for antibodies with minimal cross-reactivity

• Validate specificity using overexpression and knockout controls for multiple HOX proteins

Recommended validation experiments:

• Western blot analysis of cells overexpressing individual HOX proteins

• Peptide competition assays with peptides from multiple HOX family members

• Immunoprecipitation followed by mass spectrometry to confirm target identity

• siRNA/shRNA knockdown of specific HOX genes to confirm signal reduction

Cross-reactivity table for common commercial antibodies:

Note: This table is illustrative based on typical antibody validation patterns; for specific commercial antibodies, consult manufacturer data.

The polyclonal HOXB2 antibody described in the search results targets amino acids 65-160 , a region that should be analyzed for homology with other HOX proteins to assess potential cross-reactivity before use in critical experiments.

What are the most effective approaches for detecting low-abundance HOXB2/hoxb2a in samples with limited material?

Detecting low-abundance HOXB2/hoxb2a requires specialized techniques:

Signal amplification methods:

• Tyramide signal amplification (TSA): Can increase detection sensitivity by 10-100 fold for IHC/IF

• Polymer-based detection systems: HRP-polymer conjugates provide enhanced sensitivity over traditional ABC methods

• Proximity ligation assay (PLA): Enables single-molecule detection through rolling circle amplification

• Highly sensitive ELISA formats:

  • Electrochemiluminescence (ECL)-based detection

  • Digital ELISA platforms (e.g., Simoa) with single-molecule sensitivity

Sample enrichment strategies:

• Nuclear fractionation to concentrate transcription factors

• Phospho-protein enrichment if studying activated HOXB2/hoxb2a

• Laser capture microdissection for tissue-specific analysis

Protocol optimization parameters:

• Extended primary antibody incubation (overnight at 4°C)

• Optimized blocking to improve signal-to-noise ratio

• Enhanced chromogen/substrate development time

• Use of signal enhancers like copper sulfate for DAB enhancement

The HRP-conjugated HOXB2 antibody mentioned in the search results would be compatible with amplification systems like TSA, potentially enabling detection of low-abundance HOXB2 in challenging samples.

How can researchers investigate the epigenetic regulation of HOXB2/hoxb2a expression?

Several complementary approaches can reveal epigenetic mechanisms controlling HOXB2/hoxb2a:

Chromatin modification analysis:

• ChIP-seq for histone modifications at the HOXB2/hoxb2a locus

  • H3K27ac and H4ac (active enhancers/promoters)

  • H3K4me3 (active promoters)

  • H3K27me3 (repressed regions)

• ATAC-seq to assess chromatin accessibility

• CUT&RUN for higher resolution of chromatin marks

DNA methylation analysis:

• Bisulfite sequencing of the HOXB2/hoxb2a promoter

• Methylation-specific PCR for targeted analysis

• Array-based methylation profiling

Non-coding RNA interactions:

• RNA immunoprecipitation (RIP) to detect interactions with regulatory RNAs

• CHART or RAP to identify RNA-chromatin interactions

• RNA-protein crosslinking methods (CLIP, PAR-CLIP)

Research has shown that the hoxb2a promoter exhibits early epigenetic priming during development, with H3K27ac and H4ac marks present by 2 hpf, H3K4me3 appearing by 6 hpf, and H3K27me3 repressive marks being reduced upon TALE factor binding . Additionally, the long non-coding RNA HOXB-AS1 forms a complex with the lysine methyltransferase SMYD3 to regulate HOXB2 expression through H3K4me3 enrichment . These mechanisms may be context-dependent and differ between development and disease states.

What are the most rigorous approaches for validating antibody specificity for HOXB2/hoxb2a detection in critical experiments?

Comprehensive validation requires a multi-pronged approach:

Essential validation experiments:

• Western blot analysis:

  • Wild-type vs. HOXB2/hoxb2a knockout/knockdown samples

  • Detection of a single band at the expected molecular weight (~41 kDa for human HOXB2)

  • Comparison across multiple antibodies targeting different epitopes

• Immunocytochemistry/Immunohistochemistry validation:

  • Comparison of staining patterns with subcellular localization data

  • siRNA/shRNA knockdown controls

  • Peptide competition assays

  • Comparison between different fixation methods

• CRISPR-based validation:

  • Complete knockout cell lines as negative controls

  • Epitope-tagged endogenous protein lines for parallel detection

  • CRISPR interference (CRISPRi) for partial knockdown controls

Validation score template:

Recommendation: Proceed with experiments only if total score ≥15/21

The polyclonal HOXB2 antibody described in the search results has been validated for ELISA, IHC on frozen sections, and IHC on paraffin-embedded sections specifically in rat samples , but additional validation would be necessary when using it for other applications or in other species.

How can HOXB2/hoxb2a antibodies contribute to understanding the interplay between Hox genes and TALE factors during development?

TALE (Three Amino acid Loop Extension) transcription factors like Pbx and Prep are critical cofactors for Hox proteins. Research approaches to study this interplay include:

Co-immunoprecipitation strategies:

• Sequential ChIP (ChIP-reChIP) to identify co-occupied genomic regions

• Proximity-dependent biotinylation (BioID, TurboID) to capture transient interactions

• Mass spectrometry to identify complex components and post-translational modifications

Functional genomics approaches:

• CRISPR screening of TALE factors and associated regulatory elements

• Synthetic enhancer constructs to dissect cooperative binding requirements

• Inducible degradation systems to study temporal requirements

Developmental timing analysis:

• ChIP-seq time course experiments during development

• Live imaging with tagged proteins to track dynamic interactions

• Single-cell approaches to capture heterogeneity in Hox-TALE interactions

Research has shown that TALE factors (Pbx4 and Prep1) are involved in the regulation of hoxb2a expression, with these factors potentially protecting the hoxb2a locus from the repressive properties of H3K27me3 marks and promoting H3K4me3 enrichment . The expression of hoxb1a and hoxb2a is maintained by Hoxb1a after initial activation by Hoxb1b , demonstrating the complex regulatory network governing Hox gene expression during development.

What are the emerging applications of HOXB2/hoxb2a antibodies in cancer research and potential therapeutic development?

HOXB2's role in cancer biology opens several research directions:

Diagnostic and prognostic applications:

• Development of HOXB2-based tissue microarray analysis for patient stratification

• Multiplex immunohistochemistry to correlate HOXB2 with other markers

• Liquid biopsy approaches to detect HOXB2 in circulating tumor cells

Therapeutic targeting strategies:

• Identification of synthetic lethal interactions in HOXB2-low cancers

• Development of proteolysis-targeting chimeras (PROTACs) to modulate HOXB2 levels

• Epigenetic drugs targeting the HOXB-AS1/SMYD3 complex that regulates HOXB2

Combination therapy approaches:

• HOXB2 status as a biomarker for response to ECM-targeting therapies

• Integration with immune checkpoint inhibitor response prediction

• Synthetic lethal screening in HOXB2-deficient backgrounds

Research has demonstrated that HOXB2 has a tumor-suppressive role in triple-negative breast cancer by maintaining ECM organization and restraining metastatic capabilities . The forced expression of HOXB2 effectively prevented TNBC progression and metastasis in mouse xenograft models , suggesting therapeutic potential. Additionally, the identification of the HOXB-AS1/SMYD3 complex as an epigenetic regulator of HOXB2 expression provides another potential therapeutic target .

How can advanced antibody engineering approaches be applied to develop novel tools for HOXB2/hoxb2a research?

Innovative antibody technologies offer new research possibilities:

Engineered antibody formats:

• Single-domain antibodies (nanobodies): Smaller size for improved tissue penetration and intracellular applications

• Bispecific antibodies: Simultaneously targeting HOXB2 and partner proteins

• Intrabodies: Engineered for expression and function within specific cellular compartments

Functionalized antibody applications:

• Antibody-DNA conjugates for proximity-based DNA detection (Immuno-SABER)

• Split enzyme complementation for studying protein-protein interactions

• Antibody-fluorophore conjugates with environment-sensitive dyes to detect conformational changes

CRISPR-based epitope tagging:

• CRISPR knock-in of small epitope tags to endogenous HOXB2/hoxb2a

• Degron tagging for controlled protein degradation studies

• Split-GFP complementation for visualization of endogenous protein

These advanced tools could significantly enhance our ability to study HOXB2/hoxb2a dynamics in living systems and provide new insights into its roles in development and disease. While standard polyclonal and monoclonal antibodies like the HRP-conjugated HOXB2 antibody mentioned in the search results remain valuable for established applications, these emerging technologies represent the future direction of HOXB2/hoxb2a research.